436 related articles for article (PubMed ID: 24713310)
1. Tapentadol potentiates descending pain inhibition in chronic pain patients with diabetic polyneuropathy.
Niesters M; Proto PL; Aarts L; Sarton EY; Drewes AM; Dahan A
Br J Anaesth; 2014 Jul; 113(1):148-56. PubMed ID: 24713310
[TBL] [Abstract][Full Text] [Related]
2. A Randomized Controlled Trial on the Effect of Tapentadol and Morphine on Conditioned Pain Modulation in Healthy Volunteers.
Martini C; van Velzen M; Drewes A; Aarts L; Dahan A; Niesters M
PLoS One; 2015; 10(6):e0128997. PubMed ID: 26076171
[TBL] [Abstract][Full Text] [Related]
3. Safety and efficacy of tapentadol ER in patients with painful diabetic peripheral neuropathy: results of a randomized-withdrawal, placebo-controlled trial.
Schwartz S; Etropolski M; Shapiro DY; Okamoto A; Lange R; Haeussler J; Rauschkolb C
Curr Med Res Opin; 2011 Jan; 27(1):151-62. PubMed ID: 21162697
[TBL] [Abstract][Full Text] [Related]
4. Cornea nerve fibre state determines analgesic response to tapentadol in fibromyalgia patients without effective endogenous pain modulation.
van de Donk T; van Velzen M; Dahan A; Niesters M
Eur J Pain; 2019 Oct; 23(9):1586-1595. PubMed ID: 31162787
[TBL] [Abstract][Full Text] [Related]
5. Tapentadol, but not morphine, selectively inhibits disease-related thermal hyperalgesia in a mouse model of diabetic neuropathic pain.
Christoph T; De Vry J; Tzschentke TM
Neurosci Lett; 2010 Feb; 470(2):91-4. PubMed ID: 20026182
[TBL] [Abstract][Full Text] [Related]
6. Ready conversion of patients with well-controlled, moderate to severe, chronic malignant tumor-related pain on other opioids to tapentadol extended release.
Imanaka K; Tominaga Y; Etropolski M; Ohashi H; Hirose K; Matsumura T
Clin Drug Investig; 2014 Jul; 34(7):501-11. PubMed ID: 24906437
[TBL] [Abstract][Full Text] [Related]
7. A randomized withdrawal, placebo-controlled study evaluating the efficacy and tolerability of tapentadol extended release in patients with chronic painful diabetic peripheral neuropathy.
Vinik AI; Shapiro DY; Rauschkolb C; Lange B; Karcher K; Pennett D; Etropolski MS
Diabetes Care; 2014 Aug; 37(8):2302-9. PubMed ID: 24848284
[TBL] [Abstract][Full Text] [Related]
8. Clinical value of tapentadol extended-release in painful diabetic peripheral neuropathy.
Desai B; Freeman E; Huang E; Hung A; Knapp E; Breunig IM; McPherson ML; Shaya FT
Expert Rev Clin Pharmacol; 2014 Mar; 7(2):203-9. PubMed ID: 24524594
[TBL] [Abstract][Full Text] [Related]
9. Tapentadol prolonged release for managing moderate to severe, chronic malignant tumor-related pain.
Kress HG; Koch ED; Kosturski H; Steup A; Karcher K; Lange B; Dogan C; Etropolski MS; Eerdekens M
Pain Physician; 2014; 17(4):329-43. PubMed ID: 25054392
[TBL] [Abstract][Full Text] [Related]
10. Tapentadol-ER for the treatment of diabetic peripheral neuropathy.
Games G; Hutchison A
Consult Pharm; 2013 Oct; 28(10):672-5. PubMed ID: 24129223
[TBL] [Abstract][Full Text] [Related]
11. Unique pharmacology of tapentadol for treating acute and chronic pain.
Knezevic NN; Tverdohleb T; Knezevic I; Candido KD
Expert Opin Drug Metab Toxicol; 2015; 11(9):1475-92. PubMed ID: 26215077
[TBL] [Abstract][Full Text] [Related]
12. The antinociceptive and antihyperalgesic effect of tapentadol is partially retained in OPRM1 (μ-opioid receptor) knockout mice.
Kögel B; De Vry J; Tzschentke TM; Christoph T
Neurosci Lett; 2011 Mar; 491(2):104-7. PubMed ID: 21232580
[TBL] [Abstract][Full Text] [Related]
13. Differential contribution of opioid and noradrenergic mechanisms of tapentadol in rat models of nociceptive and neuropathic pain.
Schröder W; Vry JD; Tzschentke TM; Jahnel U; Christoph T
Eur J Pain; 2010 Sep; 14(8):814-21. PubMed ID: 20541444
[TBL] [Abstract][Full Text] [Related]
14. Practical considerations for the use of tapentadol prolonged release for the management of severe chronic pain.
Sánchez Del Águila MJ; Schenk M; Kern KU; Drost T; Steigerwald I
Clin Ther; 2015 Jan; 37(1):94-113. PubMed ID: 25108647
[TBL] [Abstract][Full Text] [Related]
15. Methodological Issues in Conducting Pilot Trials in Chronic Pain as Randomized, Double-blind, Placebo-controlled Studies.
Tominaga Y; Koga H; Uchida N; Wanibe M; Hirose K; Matsumura T; Okamoto A; Richarz U; Etropolski M
Drug Res (Stuttg); 2016 Jul; 66(7):363-70. PubMed ID: 27224908
[TBL] [Abstract][Full Text] [Related]
16. Spinal-supraspinal and intrinsic μ-opioid receptor agonist-norepinephrine reuptake inhibitor (MOR-NRI) synergy of tapentadol in diabetic heat hyperalgesia in mice.
Christoph T; Schröder W; Tallarida RJ; De Vry J; Tzschentke TM
J Pharmacol Exp Ther; 2013 Dec; 347(3):794-801. PubMed ID: 24051022
[TBL] [Abstract][Full Text] [Related]
17. Dose conversion between tapentadol immediate and extended release for low back pain.
Etropolski MS; Okamoto A; Shapiro DY; Rauschkolb C
Pain Physician; 2010; 13(1):61-70. PubMed ID: 20119464
[TBL] [Abstract][Full Text] [Related]
18. (-)-(1R,2R)-3-(3-dimethylamino-1-ethyl-2-methyl-propyl)-phenol hydrochloride (tapentadol HCl): a novel mu-opioid receptor agonist/norepinephrine reuptake inhibitor with broad-spectrum analgesic properties.
Tzschentke TM; Christoph T; Kögel B; Schiene K; Hennies HH; Englberger W; Haurand M; Jahnel U; Cremers TI; Friderichs E; De Vry J
J Pharmacol Exp Ther; 2007 Oct; 323(1):265-76. PubMed ID: 17656655
[TBL] [Abstract][Full Text] [Related]
19. [Tapentadol is a new, strongly efficative analgeticum with dual effect mechanisms].
Staahl C; Drewes AM; Jensen NH
Ugeskr Laeger; 2011 Jun; 173(25):1796-9. PubMed ID: 21689507
[TBL] [Abstract][Full Text] [Related]
20. Single dose analgesic efficacy of tapentadol in postsurgical dental pain: the results of a randomized, double-blind, placebo-controlled study.
Kleinert R; Lange C; Steup A; Black P; Goldberg J; Desjardins P
Anesth Analg; 2008 Dec; 107(6):2048-55. PubMed ID: 19020157
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
